Premium
Cyclic Interferon Gamma Treatment of Patients with Metastatic Renal Carcinoma
Author(s) -
GRUPS J. W.,
FROHMÜLLER H. G. W.
Publication year - 1989
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1989.tb06000.x
Subject(s) - medicine , renal cell carcinoma , renal carcinoma , interferon , carcinoma , disease , metastatic carcinoma , gastroenterology , oncology , immunology
Summary— The treatment of metastatic renal carcinoma is still unsatisfactory because of the lack of effective systemic therapy. In 14 patients with metastatic renal carcinoma an attempt was made to influence the course of the disease by administration of recombinant human interferon (rHu‐IFN) gamma; 9 patients were evaluated after treatment. There was partial remission in 3 patients, stable disease in 2 and tumour progression in 4. The cyclic application of rHu‐IFN at a dose of 0.25 mg/day for 8 days, with treatment‐free intervals of 3 to 4 weeks, was tolerated well. Side effects consisted mainly of fever and leucocytopenia. From this small series it seems that cyclic IFN gamma treatment might be helpful in some cases of metastatic renal carcinoma.